Day One Biopharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDDay One Biopharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 70% provides fundamental context to the price action. However, with RSI at 80, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $21.46 | +0.32% | ABOVE |
| 50 SMA | $18.21 | +18.22% | ABOVE |
| 100 SMA | $14.07 | +53.00% | ABOVE |
| 150 SMA | $12.00 | +79.44% | ABOVE |
| 200 SMA | $10.72 | +100.77% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DAWN in an uptrend right now?
DAWN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, DAWN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is DAWN overbought or oversold?
DAWN's RSI (14) is 80. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is DAWN outperforming the market?
DAWN has a Relative Strength (RS) Rating of 97 out of 99. Yes, DAWN is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is DAWN in its 52-week range?
DAWN is trading at $21.53, which is 100% of its 52-week high ($21.53) and 100% above its 52-week low ($5.64).
How volatile is DAWN?
DAWN has a Beta of 0.35 and 52-week volatility of 101%. It's less volatile than the S&P 500 - generally more stable.